UNIGE document Scientific Article
previous document  unige:84841  next document
add to browser collection

Drug Pricing Evolution in Hepatitis C.

Riguzzi, Marco
Published in PLOS ONE. 2016, vol. 11, no. 6, p. e0157098
Abstract We aimed to determine the association between the stepwise increase in the sustained viral response (SVR) and Swiss and United States (US) market prices of drug regimens for treatment-naive, genotype 1 chronic hepatitis C virus (HCV) infection in the last 25 years. We identified the following five steps in the development of HCV treatment regimens: 1) interferon (IFN)-α monotherapy in the early '90s, 2) IFN-α in combination with ribavirin (RBV), 3) pegylated (peg) IFN-α in combination with RBV, 4) the first direct acting antivirals (DAAs) (telaprevir and boceprevir) in combination with pegIFN-α and RBV, and 5) newer DAA-based regimens, such as sofosbuvir (which is or is not combined with ledipasvir) and fixed-dose combination of ritonavir-boosted paritaprevir and ombitasvir in combination with dasabuvir.
PMID: 27310294
Full text
Article (Published version) (726 Kb) - public document Free access
Research groups Etudes et traitement de l'hépatite C et B (554)
Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) (585)
Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
(ISO format)
VERNAZ-HEGI, Nathalie et al. Drug Pricing Evolution in Hepatitis C. In: PLOS ONE, 2016, vol. 11, n° 6, p. e0157098. doi: 10.1371/journal.pone.0157098 https://archive-ouverte.unige.ch/unige:84841

849 hits



Deposited on : 2016-06-29

Export document
Format :
Citation style :